Novel cytotoxic regimens in gastric cancer

European Journal of Cancer, Supplement

Volumn 4, Issue 10, 2006, Pages 14-18

  Van Cutsem, Eric ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Chemotherapy; Clinical trial; Docetaxel; Gastric cancer; novel; Oxaliplatin

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPIRUBICIN; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IMATINIB; IRINOTECAN; OXALIPLATIN; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB;

ADVANCED CANCER; ANEMIA; ARTERY THROMBOSIS; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CONTINUOUS INFUSION; DEHYDRATION; DIARRHEA; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; EUROPE; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; STOMACH CANCER; TREATMENT OUTCOME; UNITED STATES; VOMITING;

EID: 33845459108     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(06)70004-0     Document Type: Article

References (21)

1. Moiseyenko V., Ajani J., Tjulandin S., et al. Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) in patients (pts) with metastatic gastric adenocarcinoma. J Clin Oncol 23 Suppl 16 (2005) 308s (Abstract 4002)
2. Moiseyenko V, Van Cutsem E, Tjulandin S, et al. Adding docetaxel to cisplatin-5-fluorouracil improves quality of life in advanced gastric cancer: a Phase III trial. 7th World Congress on Gastro-intestinal Cancer, Barcelona, Spain, 15-18 June 2005 (Abstract O-013).
3. Van Cutsem E, Moiseyenko V, Tjulandin S, et al. Docetaxel when added to cisplatin-5-fluorouracil improves survival in advanced gastric cancer: a Phase III trial. 7th World Congress on Gastro-intestinal Cancer, Barcelona, Spain, 15-18 June 2005 (Abstract O-012).
4. Tebbutt N., Gebski V., Strickland A., et al. Randomized phase II study evaluating weekly docetaxel in combination with cisplatin and 5FU or capecitabine in metastatic oesophago-gastric cancer. J Clin Oncol 24 Suppl 18 (2006) 194s (Abstract 4067)
5. Cunningham D., Rao S., Starling N., et al. Randomized multicenter phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: the REAL 2 trial. J Clin Oncol 24 Suppl 18 (2006) 182s (Abstract LBA4017)
6. Richards D., Wilfong L., Reznick D., et al. Phase II multicenter trial of docetaxel+oxaliplatin in stage IV gastroesophageal and/or stomach cancer. J Clin Oncol 24 Suppl 18 (2006) 195s (Abstract 4071)
7. Barone C, Basso M, Quirino M, et al. Docetaxel and oxaliplatin combination as second line treatment in patients with advanced gastric cancer. ASCO Gastro-intestinal Cancers Symposium, Hollywood, Florida, 27-29 January 2005 (Abstract 27).
8. Dima G., Caputo A., De Simone R., et al. Phase II study of docetaxel, oxaliplatin, and folinic acid in locally advanced or metastatic gastric cancer patients. Ann Oncol 15 Suppl 7 (2005) (Abstract E27)
9. Kang Y., Kang W., Shin D., et al. Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): efficacy and safety results. J Clin Oncol 24 Suppl 18 (2006) 183s (Abstract LBA4018)
10. Chun J., Kim H., Lee J., et al. Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer. Am J Clin Oncol 28 (2005) 188-194
11. Lorenzen S., Duyster J., Lersch C., et al. Three-weekly docetaxel (T) plus capecitabine (X) in 1 st and 2nd line metastatic esophageal cancer (MEC): final results of the Phase II DACAPO trial. J Clin Oncol 23 Suppl 16 (2005) 343s (Abstract 4142)
12. Kim J., Sohn S., Kim D., Baek J., et al. Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer. Oncology 68 (2005) 190-195
13. Thuss-Patience P., Kretzschmar A., Loew A., et al. Capecitabine and docetaxel in advanced gastric adenocarcinoma, an ongoing phase II study. J Clin Oncol 23 Suppl 16 (2005) 343s (Abstract 4224)
14. Giordano K., Jatoi A., Stella P., et al. Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group. Ann Oncol 17 (2006) 652-656
15. Yoshida K., Ninomiya M., Takakura N., et al. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 12 (2006) 3402-3407
16. Dank M., Zaluski J., Barone C., et al. Randomized phase 3 trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) vs. CDDP + 5FU in 1 stline advanced gastric cancer patients. J Clin Oncol 23 Suppl 16S (2005) 308s (Abstract 4003)
17. Doi T., Koizumi W., Siena S., et al. Efficacy, tolerability and pharmacokinetics of gefitinib (ZD1839) in pretreated patients with metastatic gastric cancer. Proc Am Soc Clin Oncol 22 (2003) (Abstract 1036)
18. Dragovich T, McCoy S, Urba SG, et al. SWOG 0127: Phase II trial of erlotinib in GEJ and gastric carcinomas. ASCO Gastrointestinal Cancers Symposium, Hollywood, Florida, 27-29 January 2005 (Abstract 49).
19. Enzinger PC, Fidias P, Meyerhardt J, et al. Phase II study of bevacizumab and docetaxel in metastatic esophageal and gastric cancer. ASCO Gastrointestinal Cancers Symposium, San Francisco, California, 26-28 January 2006 (Abstract 68).
20. Shah M., Ramanathan R., Ilson D., et al. Final results of a multicenter phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with metastatic gastric or gastroesophageal (GEJ) adenocarcinoma (NCI #6447). J Clin Oncol 24 Suppl 18 (2006) 183s (Abstract 4020)
21. Pinto C., Diabio F., Siena S., et al. Phase II study of cetuximab plus FOLFIRI as first-line treatment in patients with unresectable/metastatic gastric or gastroesophageal junction (GEJ)-adenocarcinoma (FOLCETUX study): preliminary results. J Clin Oncol 24 Suppl 18 (2006) 186s (Abstract 4031)